Dr. Meredith Faggen, MD

Dr. Faggen practices at Breast Care Center - HOPD in South Weymouth, Massachusetts.

Dr. Faggen's NPI, 1215093968, was assigned on December 28, 2006. Dr. Faggen graduated from Tulane School of Medicine in 2002. Dr. Faggen's Rhode Island license number on file is MD12408.

Dr. Faggen's primary practice is Breast Care Center - HOPD, at 101 Columbian Street, South Weymouth, MA 02190.

Dr. Faggen's primary practice is Breast Care Center - HOPD in South Weymouth, Massachusetts. Dr. Faggen is also affiliated with Dana-Farber Cancer Institute. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Faggen to 2 more hospitals and 1 hospice, each named with a free account. Dr. Faggen's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Faggen practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Faggen's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Faggen is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Faggen's licenses on file in 3 states: Rhode Island, Massachusetts and Connecticut.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer, lymphoma and multiple myeloma among the conditions Dr. Faggen treats.

CMS data shows 1,043 Medicare services from Dr. Faggen across 6 procedure codes in 2024, for 560 Medicare patients. Medicare paid $70,592 for them.

CMS counts 560 Medicare patients who saw Dr. Faggen in 2024. The largest group is 75 to 84, with 237 patients. 75% of them have high cholesterol, and 74% have cancer. 10% are also on Medicaid. Their average risk score is 1.42, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Faggen's median patient age at 71, with 86% women.

In 2024, Dr. Faggen wrote 1,636 Medicare Part D claims for 384 patients. 78% of them were for generic drugs. CMS names the drug for 1,290 of them, across 36 drugs with 11 or more claims each, at $3,352,798 in total drug cost. In 2023, CMS named 1,175 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Faggen for performance year 2024, reported as part of a group. Dr. Faggen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Faggen as offering telehealth.

Dmand AI links 16 papers to Dr. Faggen, published from 2020 to 2025. 2020 was the busiest year, with 3. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Receptor, ErbB-2. Dr. Faggen has published most often in Breast Cancer Res Treat. Dr. Faggen's most frequent co-authors are Sara Michell Tolaney, MD, Douglas J. Weckstein, MD and Ann H. Partridge, MD, MPH.

Dmand AI links Dr. Faggen to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Breast Neoplasms, Neoplasm Metastasis and Breast Diseases. Open Payments lists research payments to Dr. Faggen that name 1 trial.

CMS Open Payments shows 7 general payments to Dr. Faggen from 4 drug and device companies from 2017 to 2025. Education make up the largest share, 67% of the total. Janssen Pharmaceuticals, Inc paid the most, $154. It also lists 1 research payment totaling $938 in 2023, naming 1 clinical trial.

Dr. Faggen graduated from Tulane School of Medicine in 2002.

Dr. Faggen is in network with 12 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.